Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SI | P14410 | 1/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.45 |
| ▸ | SAT1 | P21673 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680899 | 1.00 | MGAM (0.45) | MGAMGAASIMGAM2SAT1 | |
| SCHEMBL2721040 | 0.88 | — | — | |
| SCHEMBL20794227 | 0.87 | KMT2A (0.46) | MGAMGAASIMGAM2SAT1 | |
| SCHEMBL20794430 | 0.85 | SAT1 (0.47) | MGAMGAASIMGAM2SAT1 | |
| SCHEMBL679333 | 0.84 | MEN1 (0.41) | MGAMGAASIMGAM2KMT2A | |
| SCHEMBL679334 | 0.84 | MEN1 (0.41) | MGAMGAASIMGAM2KMT2A | |
| Hydrochloric Acid SCHEMBL17048788 | 0.84 | MEN1 (0.41) | MGAMGAASIMGAM2SAT1 | |
| SCHEMBL21706789 | 0.83 | KMT2A (0.40) | MGAMGAASIMGAM2KMT2A | |
| SCHEMBL14389978 | 0.82 | MGAM (0.44) | MGAMGAASIMGAM2KMT2A | |
| SCHEMBL14389976 | 0.82 | MGAM (0.44) | MGAMGAASIMGAM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533977-B2 | Oxazolidinone derivative as CETP inhibitor, its preparation method, and pharmaceutical composition comprising the same | DONG-A ST CO., LTD. (KR) | 2017-01-03 | — | — | US | disclosed |
| US-20160039804-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A ST CO., LTD. (KR) | 2016-02-11 | — | — | US | disclosed |
| EP-2978761-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Dong-A ST Co., Ltd. (KR) | 2016-02-03 | — | — | EP | disclosed |
| CN-105102454-A | Novel oxazolidinone derivative as cetp inhibitor, its preparation method, and pharmaceutical composition comprising the same | DONG A ST CO LTD | 2015-11-25 | — | — | CN | disclosed |
| EP-2149563-B9 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2149563-B1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| WO-2014157994-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A ST CO.,LTD (KR) | 2014-10-02 | — | — | WO | disclosed |
| US-8841478-B2 | Method for preparing trans-{4-[(alkylamino) methyl]- cyclohexyl}acetic acid ester | KOWA COMPANY, LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| EP-2383253-B1 | METHOD FOR MANUFACTURING TRANS-{4-[(ALKYL AMINO) METHYL]CYCLOHEXYL} ACETIC ESTER | KOWA CO (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2008-06-19 | — | — | US | disclosed |
| US-7332514-B2 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2008-02-19 | — | — | US | disclosed |
| WO-2007128568-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007128568-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2007-11-15 | — | — | WO | disclosed |
| EP-1829858-A2 | Dibenzylamine compounds and pharmaceutical use thereof | Japan Tobacco, Inc. (JP) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007073934-A1 | PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007073934-A1 | PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
| EP-1533292-B1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2007-02-14 | — | — | EP | disclosed |
| EP-1533292-A1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | CETP, CES1, APOB | MGAM 3963/4885GAA 2778/4885SI 3410/4885 |
| US-20080146620-A1 | Dibenzylamine Compounds and Pharmaceutical Use Thereof | CETP, PCSK9, CES1 | MGAM 3970/4885GAA 2713/4885SI 3249/4885 |
| US-20160039804-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AS CETP INHIBITOR, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CETP, MTTP, APOB | MGAM 1167/4885GAA 404/4885SI 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.